Welcome Message

Welcome Message
wei

President   WEI Lai, MD

Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital

School of Clinical Medicine, Tsinghua University

Dear Friends and Colleagues,

On behalf of the Asia-Pacific Association for the Study of the Liver (APASL) and Chinese Foundation for Hepatitis Prevention and Control (CFHPC), we are delighted to invite you to join us in Beijing from 26-30 March 2025 for the 34th Annual Meeting of APASL (APASL 2025 BEIJING).

Under the theme “Multidisciplinary Collaboration For Elimination & Cure”, the five-day scientific programme will embrace diverse topics, ranging from basic research to clinical management including drug discovery, interventional and surgical procedures, covering viral hepatitis to liver cancer. At the end of each day, there will be an interprofessional forum dedicated to enhancing communication among various disciplines. Additionally, joint symposium will be held to foster international collaboration, share experiences in prevention and build partnerships in support of national hepatitis policy-making towards elimination of viral hepatitis by 2030.

Apart from the invited lectures delivered by the renowned speakers from around the world, APASL 2025 BEIJING will feature proffered abstracts selected for oral, poster and award presentations. This is an excellent opportunity for the researchers and the industry professionals to showcase their research findings and ideas.

Beyond academic exchange, we will also have the opportunity to reconnect with old friends and make new ones at our traditional social event, “Culture Night”.

We cherish the wonderful memories of 2010, when the APASL Annual Meeting was first held in mainland China, bringing together 4645 participants from worldwide. Over the past 15 years, we have made many valuable connections and fought against liver disease together. During the time, we have witnessed the introduction of DAAs for hepatitis C, immunotherapy for liver cancer and advanced interventional technologies for the diagnosis and treatment. The recent approval of the first drug for NASH by the FDA is a particularly exciting development. We are confident that this progress will continue in the years to come with our collective effort.

We look forward to welcoming you to Beijing for an unforgettable and productive meeting. Together, let us collaborate, innovate, and strive towards the elimination and cure.

President: WEI Lai, MD

March 2024